RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $4.00 Consensus Target Price from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $4.00.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock traded up $0.01 during trading on Friday, hitting $0.76. The stock had a trading volume of 159,619 shares, compared to its average volume of 861,863. RAPT Therapeutics has a 12 month low of $0.73 and a 12 month high of $4.83. The firm's fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.24. The stock has a market cap of $100.41 million, a PE ratio of -0.27 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23. Analysts expect that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Callan Family Office LLC raised its holdings in shares of RAPT Therapeutics by 53.9% during the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the period. Nuveen LLC bought a new position in RAPT Therapeutics in the 1st quarter worth approximately $143,000. Invesco Ltd. boosted its position in shares of RAPT Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock valued at $72,000 after acquiring an additional 47,391 shares during the period. Charles Schwab Investment Management Inc. grew its position in RAPT Therapeutics by 112.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company's stock worth $184,000 after purchasing an additional 79,967 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in RAPT Therapeutics by 27.7% during the first quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company's stock valued at $139,000 after acquiring an additional 24,662 shares during the period. Institutional investors and hedge funds own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.